Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03554317 2024-02-20

COMBAT-CRPC

Phase 2 Completed

45 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT05150236 2023-12-15

ANZUP2001

Phase 2 Unknown

93 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT03879122 2022-10-26

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Phase 2/3 Unknown

135 enrolled

Genitourinary

Prostatic Neoplasms

NCT03061539 2022-09-28

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Phase 2 Active not recruiting

380 enrolled

Genitourinary

Prostatic Neoplasms

NCT02601014 2022-02-03

STARVE-PC

Phase 2 Completed

32 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT03040791 2021-08-26

ImmunoProst

Phase 2 Unknown

38 enrolled

Genitourinary

Prostatic Neoplasms

NCT03572478 2021-03-09

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

GenitourinaryGynecologic

Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

Nivolumab in Biochemically Recurrent dMMR Prostate Cancer

Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer

CHAMP

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

CheckPRO

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

COMBAT-CRPC

ANZUP2001

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

STARVE-PC

ImmunoProst

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer